This virtual conference highlights the latest advances in biomarker analytical techniques and assay methodologies that support every stage of product development from early discovery through clinical programs, with particular focus on flow cytometry, genomics, and immunohistochemistry. Sessions will explore best practices in

• Assay platform selection,
• Streamlined development,
• Validation strategies
• Management of clinical samples
• Regulatory considerations
• Reference standards,
• Bridging strategies

We will focus on biomarker analysis for a variety of therapies including: genetic and blood‑based markers, exosomes, vaccine biomarkers, and applications of flow cytometry.

By uniting scientific, regulatory, and technical perspectives, the event aims to accelerate the translation of biomarkers into reliable clinical tools, reduce development risk, and enhance patient stratification and decision‑making across the industry. This conference is designed for industry professionals working in biomarker discovery, translational sciences, clinical and nonclinical bioanalytics, QC and regulated assay development, as well as regulatory and CMC teams responsible for ensuring biomarker assays are fit‑for‑purpose throughout the product lifecycle.